Current advantage of FK 506 in cadaveric kidney transplantation.
Ciancio
G
G
Department of Surgery, University of Miami School of Medicine, Florida, USA.
Rosen
A
A
Loreto-Grand
B
B
Burke
G
G
Siquijor
A
A
Luque
C
C
Esquenazi
V
V
Miller
J
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D008775:Methylprednisolone / Q000627:therapeutic use; D010359:Patient Readmission; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D014019:Tissue Donors
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D016559:Tacrolimus; D008775:Methylprednisolone